2. Signaling Pathways
  3. JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
  4. EGFR
  5. EGFR Inhibitor

EGFR Inhibitor

EGFR Isoform Comparison

EGFR Inhibitors (744):

Cat. No. Product Name Effect Purity
  • HY-32721S
    Neratinib-d6
    		Inhibitor
    Neratinib-d6 (HKI-272-d6) is the deuterium labeled Neratinib. Neratinib (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor with IC50s of 59 nM and 92 nM for HER2 and EGFR, respectively.
  • HY-32721R
    Neratinib (Standard)
    		Inhibitor
    Neratinib (Standard) is the analytical standard of Neratinib. This product is intended for research and analytical applications. Neratinib (HKI-272) is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC50s of 59 nM and 92 nM, respectively.
  • HY-13272R
    Dacomitinib (Standard)
    		Inhibitor
    Dacomitinib (Standard) is the analytical standard of Dacomitinib. This product is intended for research and analytical applications. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively.
  • HY-12008A
    Erlotinib mesylate
    		Inhibitor
    Erlotinib mesylate (CP-358774 mesylate) inhibits purified EGFR kinase with an IC50 of 2 nM. Erlotinib (mesylate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • HY-164464
    BPI-15086
    		Inhibitor
    BPI-15086 an orally active, potent, irreversible mutant-selective inhibitor of both EGFR and T790M resistance mutations tyrosine kinase. BPI-15086 can be used for the research of non-small-cell lung cancer.
  • HY-10367R
    Canertinib (Standard)
    		Inhibitor
    Canertinib (Standard) is the analytical standard of Canertinib. This product is intended for research and analytical applications. Canertinib (CI-1033;PD-183805) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM. Canertinib is active against vaccinia virus respiratory infection in mice[1][2][3][4].
  • HY-15164AR
    Icotinib (Standard)
    		Inhibitor
    Icotinib (Standard) is the analytical standard of Icotinib. This product is intended for research and analytical applications. Icotinib (BPI-2009) is a potent and specific EGFR inhibitor with an IC50 of 5 nM; also inhibits mutant EGFRL858R, EGFRL858R/T790M, EGFRT790M and EGFRL861Q. Icotinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • HY-110045
    ZM-306416 hydrochloride
    		Inhibitor
    ZM-306416 (CB-676475) hydrochloride is a potent VEGFR inhibitor with IC50s of 0.1 μM and 2 μM for VEGFR2/KDR/Flk-1 and Flt, respectively. ZM-306416 hydrochloride is also a EGFR inhibitor with an IC50 of <10 nM.
  • HY-P991090
    YH32367
    		Inhibitor
    YH32367 (ABL105) is a bispecific HER2 and 4-1BB antibody. YH32367 induces IFN-γ secretion and thereby eliciting tumor cell death in co-culture condition with hPBMC and HER2-expressing tumor cells. YH32367 has significant anti-tumor effects.
  • HY-N14637
    Paeciloquinone C
    		Inhibitor
    Paeciloquinone C can inhibit the EGFR protein tyrosine kinase. Paeciloquinone C inhibits the V-abl protein tyrosine Kinase with an IC50 of 0.56 μM.
  • HY-W740378
    1,2,3,4-Tetrahydro Staurosporin
    		Inhibitor
    1,2,3,4-Tetrahydrostaurosporine is a derivative of Staurosporine (HY-15141) and an inhibitor of mutant EGFR (IC50=74 nM for EGFRT790M). It is selective for EGFRT790M over wild-type EGFR (IC50=390 nM). It also binds to Janus kinase 3 (JAK3).
  • HY-16069S
    Tucatinib-d6
    		Inhibitor
    Tucatinib-d6 (Irbinitinib-d6) is deuterium labeled Tucatinib. Tucatinib (Irbinitinib) is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM.
  • HY-50896S2
    Erlotinib-d4
    		Inhibitor
    Erlotinib-d4 (CP-358774-d4) is deuterium labeled Erlotinib. Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer. Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • HY-P9977A
    Amivantamab (FUT8-KO)
    		Inhibitor
    Amivantamab (FUT8-KO) is an anti-EGFR-MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells.
  • HY-50898S4
    Lapatinib-d7
    		Inhibitor
    Lapatinib-d7 (GW572016-d7) is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.
  • HY-123766
    EGFR-IN-99
    		Inhibitor
    EGFR-IN-99 (compound 1a) is a potent EGFR and HER2 Exon 20 insertion mutant inhibitor. EGFR-IN-99 has excellent antiproliferative activity against DFCI127 cells, with an EC50 of 11.5 nM. EGFR-IN-99 can be used for the research of non-small cell lung cancer (NSCLC).
  • HY-10322R
    Falnidamol (Standard)
    		Inhibitor
    Falnidamol (Standard) is the analytical standard of Falnidamol. This product is intended for research and analytical applications. Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50>10 μM). Falnidamol is a pyrimido-pyrimidine compound and has anti-cancer activity[1][2].
  • HY-101820R
    Simotinib (Standard)
    		Inhibitor
    Simotinib (Standard) is the analytical standard of Simotinib. This product is intended for research and analytical applications. Simotinib is a selective, specific, and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC50 of 19.9 nM. Antineoplastic activities[1].
  • HY-114667
    Lavendustin C6
    		Inhibitor
    Lavendustin C6 is a specific inhibitor of tyrosine kinase. Lavendustin C6 inhibits epidermal growth factor (EGF) receptor tyrosine kinase with an EC50 value of 0.05 μg/mL. Lavendustin C6 inhibits platelet-derived growth factor (PDGF)-induced inositol phosphate formation.
  • HY-135725
    D-69491 hydrochloride
    		Inhibitor
    D-69491 hydrochloride is a HER-2 tyrosine kinase inhibitor that reduces HER-2 phosphorylation, inhibits the proliferation of SKOV-3 cells, and has anticancer activity.